Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

Detalles Bibliográficos
Autores principales: Stalder, Grégoire, Suffiotti, Madeleine, Segot, Amandine, Noto, Alessandra, Pantaleo, Giuseppe, Spertini, Olivier, Obeid, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827158/
https://www.ncbi.nlm.nih.gov/pubmed/36073517
http://dx.doi.org/10.3324/haematol.2022.281221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827158/
https://www.ncbi.nlm.nih.gov/pubmed/36073517
http://dx.doi.org/10.3324/haematol.2022.281221

Ejemplares similares